For all the angst over the eye-popping prices for a pair of new gene therapies, an analysis finds the treatments are cost effective, at least for now.
The analysis examined two so-called CAR-T therapies — one is sold by Novartis for treating youngsters with advanced leukemia, and the other is sold by Gilead Sciences to treat a type of lymphoma in adults. They have a one-time cost of $475,000 and $373,000, respectively, but even at those prices, the drugs are considered more economical than standard chemotherapy treatment.
About the Author Reprints
